<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004226</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067467</org_study_id>
    <secondary_id>UAB-RAD-9601</secondary_id>
    <secondary_id>UAB-F970430006</secondary_id>
    <secondary_id>NCI-G99-1656</secondary_id>
    <nct_id>NCT00004226</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy</brief_title>
  <official_title>Phase I/II Study of High Dose Limited Volume Postoperative Reirradiation in Recurrent or Second Primary Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy following surgery&#xD;
      in treating patients who have recurrent or second primary cancer of the head and neck&#xD;
      following previous radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the survival and local control in previously irradiated patients at high risk&#xD;
           for local failure following regional resection of recurrent or second primary head and&#xD;
           neck cancer.&#xD;
&#xD;
        -  Determine the acute and late toxicities of this treatment in these patients.&#xD;
&#xD;
        -  Determine the pattern of disease failure in these patients on this treatment.&#xD;
&#xD;
        -  Determine any change in quality of life in these patients on this treatment.&#xD;
&#xD;
      OUTLINE: Patients receive fractionated doses of radiotherapy five times weekly for 6 weeks.&#xD;
&#xD;
      Quality of life is assessed prior to study, 2 months after radiotherapy, every 3 months for&#xD;
      remainder of year 1, every 4 months for years 2-3, every 6 months for years 4-5, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      Patients are followed 2 months after radiotherapy, every 3 months for year 1, every 4 months&#xD;
      for year 2, every 6 months for years 3-5, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2000</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the mucosa, recurrent (primary&#xD;
             and/or nodal), or a second primary (positive or negative nodal), of one of the&#xD;
             following:&#xD;
&#xD;
               -  Oral cavity&#xD;
&#xD;
               -  Oropharynx&#xD;
&#xD;
               -  Hypopharynx&#xD;
&#xD;
               -  Larynx&#xD;
&#xD;
               -  Paranasal sinus&#xD;
&#xD;
               -  Neck disease of unknown origin&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  No primary in the nasopharynx&#xD;
&#xD;
          -  Must have complete gross resection of disease&#xD;
&#xD;
          -  Must have positive final margins, soft tissue extension of primary, positive&#xD;
             extracapsular extension of lymph node disease, or at least 4 positive nodes without&#xD;
             extracapsular extension&#xD;
&#xD;
          -  Reirradiation field must overlap the previous field for a minimum of 3 cm in height,&#xD;
             width, and length&#xD;
&#xD;
               -  At least 6 months since prior radiotherapy with an overlap volume of at least 45&#xD;
                  Gy&#xD;
&#xD;
          -  No grade 3 or 4 toxicity for the following organ tissues:&#xD;
&#xD;
               -  RTOG grade 3 or 4 skin, subcutaneous tissue, larynx, joint, or RTOG grade 4&#xD;
                  mucous membrane or bone from prior radiotherapy&#xD;
&#xD;
          -  Radiotherapy must begin within 6-12 weeks of surgery&#xD;
&#xD;
          -  Prior radiotherapy records must be available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No history of invasive malignancy that would be expected to cause death within 3 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L. Pearlman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tampa (Haley)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

